The following three diseases were selected for the survey: rheumatoid arthritis, which is an inflammatory disease for which antibody drugs and JAK inhibitors are being developed; psoriasis, for which IL-17 antibodies and PDE4 inhibitors, in addition to TNFα and IL-12/23 antibodies, have been discovered in recent years, expanding the scope of treatment; and Alzheimer’s disease, for which the elucidation of disease mechanisms and the development of diagnostic methods and therapeutic agents are currently being actively pursued. Here, TNF is linked to psoriasis.